342 related articles for article (PubMed ID: 19943977)
1. Prion protein self-peptides modulate prion interactions and conversion.
Rigter A; Priem J; Timmers-Parohi D; Langeveld JP; van Zijderveld FG; Bossers A
BMC Biochem; 2009 Nov; 10():29. PubMed ID: 19943977
[TBL] [Abstract][Full Text] [Related]
2. Mapping of possible prion protein self-interaction domains using peptide arrays.
Rigter A; Langeveld JP; Timmers-Parohi D; Jacobs JG; Moonen PL; Bossers A
BMC Biochem; 2007 Apr; 8():6. PubMed ID: 17430579
[TBL] [Abstract][Full Text] [Related]
3. Sheep scrapie susceptibility-linked polymorphisms do not modulate the initial binding of cellular to disease-associated prion protein prior to conversion.
Rigter A; Bossers A
J Gen Virol; 2005 Sep; 86(Pt 9):2627-2634. PubMed ID: 16099922
[TBL] [Abstract][Full Text] [Related]
4. Critical significance of the region between Helix 1 and 2 for efficient dominant-negative inhibition by conversion-incompetent prion protein.
Taguchi Y; Mistica AM; Kitamoto T; Schätzl HM
PLoS Pathog; 2013; 9(6):e1003466. PubMed ID: 23825952
[TBL] [Abstract][Full Text] [Related]
5. Protein misfolding cyclic amplification of prions.
Saunders SE; Bartz JC; Shikiya RA
J Vis Exp; 2012 Nov; (69):. PubMed ID: 23168797
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the PrPc Amino-Terminal Domain in Prion Species Barriers.
Davenport KA; Henderson DM; Mathiason CK; Hoover EA
J Virol; 2016 Dec; 90(23):10752-10761. PubMed ID: 27654299
[TBL] [Abstract][Full Text] [Related]
7. Prion protein complexed to N2a cellular RNAs through its N-terminal domain forms aggregates and is toxic to murine neuroblastoma cells.
Gomes MP; Millen TA; Ferreira PS; e Silva NL; Vieira TC; Almeida MS; Silva JL; Cordeiro Y
J Biol Chem; 2008 Jul; 283(28):19616-25. PubMed ID: 18456654
[TBL] [Abstract][Full Text] [Related]
8. The octarepeat region of the prion protein is conformationally altered in PrP(Sc).
Yam AY; Gao CM; Wang X; Wu P; Peretz D
PLoS One; 2010 Feb; 5(2):e9316. PubMed ID: 20195363
[TBL] [Abstract][Full Text] [Related]
9. Conservation of a glycine-rich region in the prion protein is required for uptake of prion infectivity.
Harrison CF; Lawson VA; Coleman BM; Kim YS; Masters CL; Cappai R; Barnham KJ; Hill AF
J Biol Chem; 2010 Jun; 285(26):20213-23. PubMed ID: 20356832
[TBL] [Abstract][Full Text] [Related]
10. Strain-Dependent Prion Infection in Mice Expressing Prion Protein with Deletion of Central Residues 91-106.
Uchiyama K; Miyata H; Yamaguchi Y; Imamura M; Okazaki M; Pasiana AD; Chida J; Hara H; Atarashi R; Watanabe H; Kondoh G; Sakaguchi S
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019549
[TBL] [Abstract][Full Text] [Related]
11. Conversion efficiency of bank vole prion protein in vitro is determined by residues 155 and 170, but does not correlate with the high susceptibility of bank voles to sheep scrapie in vivo.
Piening N; Nonno R; Di Bari M; Walter S; Windl O; Agrimi U; Kretzschmar HA; Bertsch U
J Biol Chem; 2006 Apr; 281(14):9373-84. PubMed ID: 16455657
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human prion protein inhibits prion propagation in vitro.
Yuan J; Zhan YA; Abskharon R; Xiao X; Martinez MC; Zhou X; Kneale G; Mikol J; Lehmann S; Surewicz WK; Castilla J; Steyaert J; Zhang S; Kong Q; Petersen RB; Wohlkonig A; Zou WQ
Sci Rep; 2013 Oct; 3():2911. PubMed ID: 24105336
[TBL] [Abstract][Full Text] [Related]
13. Sialylation of prion protein controls the rate of prion amplification, the cross-species barrier, the ratio of PrPSc glycoform and prion infectivity.
Katorcha E; Makarava N; Savtchenko R; D'Azzo A; Baskakov IV
PLoS Pathog; 2014 Sep; 10(9):e1004366. PubMed ID: 25211026
[TBL] [Abstract][Full Text] [Related]
14. Immunological mimicry of PrPC-PrPSc interactions: antibody-induced PrP misfolding.
Li L; Guest W; Huang A; Plotkin SS; Cashman NR
Protein Eng Des Sel; 2009 Aug; 22(8):523-9. PubMed ID: 19602568
[TBL] [Abstract][Full Text] [Related]
15. Pathogenic mutations within the hydrophobic domain of the prion protein lead to the formation of protease-sensitive prion species with increased lethality.
Coleman BM; Harrison CF; Guo B; Masters CL; Barnham KJ; Lawson VA; Hill AF
J Virol; 2014 Mar; 88(5):2690-703. PubMed ID: 24352465
[TBL] [Abstract][Full Text] [Related]
16. Identifying key components of the PrPC-PrPSc replicative interface.
Abalos GC; Cruite JT; Bellon A; Hemmers S; Akagi J; Mastrianni JA; Williamson RA; Solforosi L
J Biol Chem; 2008 Dec; 283(49):34021-8. PubMed ID: 18826953
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity and Architecture of Pathological Prion Protein Assemblies: Time to Revisit the Molecular Basis of the Prion Replication Process?
Igel-Egalon A; Bohl J; Moudjou M; Herzog L; Reine F; Rezaei H; Béringue V
Viruses; 2019 May; 11(5):. PubMed ID: 31083283
[TBL] [Abstract][Full Text] [Related]
18. Different antigenicities of the N-terminal region of cellular and scrapie prion proteins.
Ushiki-Kaku Y; Iwamaru Y; Masujin K; Imamura M; Itohara S; Ogawa-Goto K; Hattori S; Yokoyama T
Microbiol Immunol; 2013 Nov; 57(11):792-6. PubMed ID: 24117858
[TBL] [Abstract][Full Text] [Related]
19. Prion protein self-interactions: a gateway to novel therapeutic strategies?
Rigter A; Langeveld JP; van Zijderveld FG; Bossers A
Vaccine; 2010 Nov; 28(49):7810-23. PubMed ID: 20932496
[TBL] [Abstract][Full Text] [Related]
20. Insight into the PrPC-->PrPSc conversion from the structures of antibody-bound ovine prion scrapie-susceptibility variants.
Eghiaian F; Grosclaude J; Lesceu S; Debey P; Doublet B; Tréguer E; Rezaei H; Knossow M
Proc Natl Acad Sci U S A; 2004 Jul; 101(28):10254-9. PubMed ID: 15240887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
